País: Singapur
Idioma: anglès
Font: HSA (Health Sciences Authority)
BISOPROLOL FUMARATE
MERCK PTE. LTD.
C07AB07
2.5 mg
TABLET, FILM COATED
BISOPROLOL FUMARATE 2.5 mg
ORAL
Prescription Only
Merck Healthcare KGaA
ACTIVE
2000-07-13
Concor 2.5 mg, film-coated tablets Concor 5 mg, film-coated tablets QUALITATIVE AND QUANTITATIVE COMPOSITION Concor 2.5 mg: Each tablet contains 2.5 mg bisoprolol fumarate. Concor 5 mg: Each tablet contains 5 mg bisoprolol fumarate. PHARMACEUTICAL FORM Film-coated tablet. Concor 2.5 mg: White, heart-shaped, scored and film-coated tablets. Concor 5 mg: Yellowish white, heart-shaped, scored and film-coated tablets. CLINICAL PARTICULARS THERAPEUTIC INDICATIONS Treatment of hypertension as well as treatment of coronary heart disease (angina pectoris). Treatment of stable chronic heart failure with reduced systolic left ventricular function in addition to ACE inhibitors, and diuretics, and optionally cardiac glycosides (for additional information see section Pharmacodynamic properties). POSOLOGY AND METHOD OF ADMINISTRATION For all indications Treatment with bisoprolol is generally a long-term therapy. Do not stop treatment abruptly or change the recommended dose without talking to your doctor first since this might lead to a transitory worsening of condition. Especially in patients with ischaemic heart disease, treatment must not be discontinued suddenly. If discontinuation is necessary, the daily dose is gradually decreased. Concor tablets are taken in the morning with or without food. They are swallowed with some liquid and not to be chewed. Treatment of hypertension or angina pectoris For both indications the dosage is 5 mg bisoprolol once daily. If necessary, the dose may be increased to 10 mg bisoprolol once daily. In all cases the dosage is adjusted individually, in particular according to the pulse rate and therapeutic success. Treatment of stable chronic heart failure Standard treatment of CHF consists of an ACE inhibitor (or an angiotensin receptor blocker in case of Llegiu el document complet
CONCOR Bisoprolol fumarate Concor 2.5 mg, film-coated tablets Concor 5 mg, film-coated tablets QUALITATIVE AND QUANTITATIVE COMPOSITION Concor 2.5 mg: Each tablet contains 2.5 mg bisoprolol fumarate. Concor 5 mg: Each tablet contains 5 mg bisoprolol fumarate. PHARMACEUTICAL FORM Film-coated tablet. Concor 2.5 mg: White, heart-shaped, scored and film-coated tablets. Concor 5 mg: Yellowish white, heart-shaped, scored and film-coated tablets. CLINICAL PARTICULARS THERAPEUTIC INDICATIONS Treatment of hypertension as well as treatment of coronary heart disease (angina pectoris). Treatment of stable chronic heart failure with reduced systolic left ventricular function in addition to ACE inhibitors, and diuretics, and optionally cardiac glycosides (for additional information see section _Pharmacodynamic properties_). POSOLOGY AND METHOD OF ADMINISTRATION For all indications Treatment with bisoprolol is generally a long-term therapy. DO NOT STOP TREATMENT ABRUPTLY OR CHANGE THE RECOMMENDED DOSE WITHOUT TALKING TO YOUR DOCTOR FIRST since this might lead to a transitory worsening of condition. Especially in patients with ischaemic heart disease, treatment must not be discontinued suddenly. If discontinuation is necessary, the daily dose is gradually decreased. Concor tablets are taken in the morning with or without food. They are swallowed with some liquid and not to be chewed. Treatment of hypertension or angina pectoris For both indications the dosage is 5 mg bisoprolol once daily. If necessary, the dose may be increased to 10 mg bisoprolol once daily. In all cases the dosage is adjusted individually, in particular according to the pulse rate and therapeutic success. Treatment of stable chronic heart failure Standard treatment of CHF consists of an ACE inhibitor (or an angiotensin receptor blocker in case of intolerance to ACE inhibitors), a beta-blocker, diuretics, and when appropriate cardiac glycosides. The initiation of treatment of stable chronic heart failure with Concor necessitates a special titration phase. Llegiu el document complet